Warnings:
Anabolic steroids do not enhanceathletic ability.

Precaution:
Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium during the course of androgenic anabolic steroid therapy. If it develops, the drug should be stopped.Caution is required in administering the agents to patients with cardiac, renal or hepatic disease. Edema may occur occasional. Concomitant administration with adrenal cortical steroids or ACTH may add to the edema.If amenorrhea or menstrual irregularities develop, the drug should be discontinued and the etiology is determined. Anabolic steroids may increase sensitivity to anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level.The insulin or oral hypoglycemic dosage may need adjustment in diabetic patients who receive anabolic steroids. Anabolic steroids may cause suppression of clotting factor II, V, VII, and X, and an increase in prothrombin time. Because of hepatoxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically Anabolic steroids should be used carefully in patients with benign prostatic hypertrophy. Serum cholesterol may increase during therapy.Therefore, caution is required in administering these agents to patients with a history of myocardial infarction or coronary artery disease. Serial determinations of serum cholesterol should be made and therapy adjusted accordingly.

Adverse Reactions:
In Males
Prepubertal : phallic enlargement; increased frequency of erections. Postpubertal : inhibition of testicular function, oligospermia; gynecomastia.

In Females:
Hirsutism ; male pattern baldness; deepening of the voice; clitoral enlargement. These changes are usually irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens. In addition, the following may occur: menstrual irregularities; masculinization of the fetus.

In Both Sexes:
Nausea; fullness; loss of appetite; vomiting; burning of the tongue; increased or decreased libido; acne (especially in females and prepubertal males); inhibition of gonadotropin secretion; bleeding in patients on concomitant anti-coagulant therapy; premature closure of epiphyses in children; jaundice. There have been rare reports of hepatocellular neophasms and peliosis hepatic in association with long-term androgenic–anabolic steroid therapy. Alterations may occur in the following clinical laboratory tests: metyrapone test; glucose tolerance tests; thyroid function tests (decrease in protein bound iodine, thyroxine-binding capacity and radioactive iodine uptake); electrolytes retention of sodium, chloride, water, potassium, phosphate, and calcium); hepatic function tests (increased BSP, serum cholesterol,SGOT, serum bilirubin, and alkaline phosphatase); blood coagulation tests (suppression of clotting factors II, V, VII, and X); decreased 17-ketosteroid excretion.

Dosage and Administration:
Methandienone® therapy is adjunctive to and not a replacement for conventional therapy. Duration of therapy will depend on the response of the condition and the appearance of adverse reactions. Therapy should be intermittent and no longer than necessary for optimal results.The usual initial adult dosage is 5 mg daily. For maintenance, 2.5 to 5 mg daily is usually sufficient. Intermittent therapy is recommended when Methandienone® is administered over long periods. For example, after six weeks of treatment, there should be an interval of two to four weeks before resuming therapy.Proper diet, particularly adequate protein intake, is required to assure the full anabolic benefits of Methandienone®.

Overdosage:
Signs and symptoms of overdosage are those associated with the known effects of the drug. See Adverse Reactions section. Treatment is symptomatic and supportive. Evacuate stomach contents by emesis and, if indicated, lavage, taking care to prevent aspiration. Monitoring of liver function is advised.

How Supplied:
Methandienone® 5 mg is supplied in bottle of 1000 pink tablets
Methandienone® 10 mg is supplied in 2 packages 100 blue tablets bottle and 500 blue tablets bottle

Do not store above 30°C or 86°F Manufactured by LA pharma S.r.l.